Jeffrey P. Castelli serves as the Chief Development Officer at Amicus Therapeutics, Inc., a position he has held since joining the company in 2013. In this role, Castelli is responsible for overseeing the clinical development and regulatory strategy of Amicus' portfolio of therapies aimed at treating rare and orphan diseases. His leadership has been instrumental in advancing the company's mission to develop innovative treatments that address unmet medical needs. Prior to joining Amicus Therapeutics, Castelli amassed a wealth of experience in the biopharmaceutical industry. He spent over a decade at Pfizer, where he held various leadership positions within the clinical development and medical affairs departments. At Pfizer, he played a key role in the development and launch of several successful products, including treatments for neurological and metabolic disorders. Castelli's expertise in clinical development and regulatory affairs has been a significant asset to Amicus, enabling the company to navigate the complex landscape of drug development and bring new therapies to patients in need. Under Castelli's guidance, Amicus Therapeutics has made significant strides in its clinical programs, most notably with the development and approval of Galafold (migalastat), a first-in-class oral precision medicine for the treatment of Fabry disease. His strategic vision and dedication to advancing rare disease research have been pivotal in positioning Amicus as a leader in the field. Castelli's commitment to improving the lives of patients with rare diseases continues to drive the company's efforts to expand its pipeline and bring new treatments to market.